CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis

Abstract

Several studies have investigated the association between CYP2C19 polymorphism and clinical outcomes of patients treated with clopidogrel, but few have noticed the difference in association between Westerners and Asians. We searched MEDLINE, EMBASE and Cochrane Library database and conducted a systematic review and meta-analysis. Thirty-six studies involving 44 655 patients with coronary artery disease (CAD) treated with clopidogrel were included, of which more than 68% had undergone percutaneous coronary intervention (PCI). The primary outcome of our interest was the recurrence of major adverse cardiovascular events (MACE) in those CAD patients. Firstly, we found that the distribution of reduced-function CYP2C19 allele varied between Westerners and Asians. Among Asians, 1 and 2 reduced-function CYP2C19 mutant allele carriers accounted for 42.5% and 10%, respectively. While among Westerners, 1 and 2 reduced-function CYP2C19 mutant allele carriers accounted for 25.5% and 2.4%, respectively. Secondly, the impact of CYP2C19 polymorphism on clinical outcomes of patients treated with clopidogrel varied with races. Among Asians, only 2 reduced-function CYP2C19 mutant allele carriers had the reduced effect of clopidogrel. And the reduced effect was significant only after the 30th day of treatment. While among Westerners, both 1 and 2 reduced-function CYP2C19 allele carriers had the reduced effect, and it mainly occurred within the first 30 days. Thirdly, the safety of clopidogrel was almost the same among races. Reduced-function allele non-carriers had higher risk for total bleeding but did not have higher risk for major bleeding. It is suggested that CYP2C19 polymorphism affects the efficacy of clopidogrel differently among Westerners and Asians.

Keywords

clopidogrel / CYP2C19 polymorphism / meta-analysis / major adverse cardiovascular events / race

References

[1] SnoepJD, HovensMM, EikenboomJC, et al. . Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J, 2007, 154(2): 221-231 PMID: 17643570

[2] FoodU. Drug Administration. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. FDA, 2010

[3] PareG, MehtaSR, YusufS, et al. . Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med, 2010, 363(18): 1704-1714 PMID: 20979470

[4] WallentinL, JamesS, StoreyRF, et al. . Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet, 2010, 376(9749): 1320-1328 PMID: 20801498

[5] LiangZY, HanYL, ZhangXL, et al. . The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention, 2013, 9(3): 316-327 PMID: 23872648

[6] NishioR, ShinkeT, OtakeH, et al. . Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese patients receiving clopidogrel. Circ J, 2012, 76(10): 2348-2355 PMID: 22785462

[7] OhIY, ParkKW, KangSH, et al. . Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart, 2012, 98(2): 39-144

[8] SawadaT, ShinkeT, ShiteJ, et al. . Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J, 2011, 75(1): 99-105 PMID: 21099121

[9] BauerT, BoumanHJ, van WerkumJW, et al. . Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ, 2011, 4(343): d4588

[10] HolmesMV, PerelP, ShahT, et al. . CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA, 2011, 306(24): 2704-2714 PMID: 22203539

[11] HulotJS, ColletJP, SilvainJ, et al. . Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol, 2010, 56(2): 134-143 PMID: 20620727

[12] JangJS, ChoKI, JinHY, et al. . Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol, 2012, 110(4): 502-508 PMID: 22591668

[13] JinB, NiHC, ShenW, et al. . Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep, 2011, 38(3): 1697-1702 PMID: 20845077

[14] LiuYP, HaoPP, ZhangMX, et al. . Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis. Thromb Res, 2011, 128(6): 593-594 PMID: 21794898

[15] MaoL, JianC, ChangzhiL, et al. . Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis, 2013, 106(10): 517-527 PMID: 24080325

[16] MegaJL, SimonT, ColletJP, et al. . Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA, 2010, 304(16): 1821-1830 PMCID: 3048820 PMID: 20978260

[17] SofiF, GiustiB, MarcucciR, et al. . Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J, 2011, 11(3): 199-206 PMID: 20351750

[18] SorichMJ, PolasekTM, WieseMD. Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thromb Haemost, 2012, 108(1): 199-200 PMID: 22552318

[19] ZabalzaM, SubiranaI, SalaJ, et al. . Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart, 2012, 98(2): 100-108 PMID: 21693476

[20] StroupDF, BerlinJA, MortonSC, et al. . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 2000, 283(15): 2008-2012 PMID: 10789670

[21] MegaJL, SimonT, ColletJ-P, et al. . Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA, 2010, 304(16): 1821-1830 PMCID: 3048820 PMID: 20978260

[22] ManM, FarmenM, DumaualC, et al. . Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010, 50(8): 929-940 PMID: 20173083

[23] ScottS, SangkuhlK, GardnerE, et al. . Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther, 2011, 90(2): 328-332 PMCID: 3234301 PMID: 21716271

[24] KangYH, LaoHY, WuH, et al. . Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. Eur J Clin Pharmacol, 2013, 69(8): 1511-1519 PMID: 23608957

[25] ColletJP, HulotJS, PenaA, et al. . Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet, 2009, 373(9660): 309-317 PMID: 19108880

[26] BhattDL, ParéG, EikelboomJW, et al. . The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J, 2012, 33(17): 2143-2150 PMID: 22450429

[27] HarmszeAM, van WerkumJW, Ten BergJM, et al. . CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J, 2010, 31(24): 3046-3053 PMID: 20833683

[28] LuoY, ZhaoY, VerdoA, et al. . Relationship between cytochrome P450 2C19* 2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. J Int Med Res, 2011, 39(5): 2012-2019 PMID: 22118006

[29] LiuY, LiuN, LiW, et al. . Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention. Pharmacology, 2013, 91(3–4): 165-172 PMID: 23429358

[30] MalekLA, KisielB, SpiewakM, et al. . Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J, 2008, 72(7): 1165-1169 PMID: 18577829

[31] SibbingD, StegherrJ, LatzW, et al. . Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J, 2009, 30(8): 916-922 PMID: 19193675

[32] SimonT, VerstuyftC, Mary-KrauseM, et al. . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009, 360(4): 363-375 PMID: 19106083

[33] WuH, QianJ, XuJ, et al. . Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenet Genomics, 2012, 22(12): 887-890 PMID: 22990067

[34] YamamotoK, HokimotoS, ChitoseT, et al. . Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol, 2011, 57(2): 194-201 PMID: 21168310

[35] MegaJL, CloseSL, WiviottSD, et al. . Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med, 2009, 360(4): 354-362 PMID: 19106084

[36] AndersonCD, BiffiA, GreenbergSM, et al. . Personalized approaches to clopidogrel therapy: are we there yet?. Stroke, 2010, 41(12): 2997-3002 PMCID: 3014683 PMID: 21030701

[37] HarmszeAM, van WerkumJW, HackengCM, et al. . The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics, 2012, 22(3): 169-175 PMID: 22228204

[38] HarmszeAM, van WerkumJW, SouvereinPC, et al. . Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost, 2011, 9(10): 1892-1901 PMID: 21854540

[39] CutlipDE, WindeckerS, MehranR, et al. . Clinical end points in coronary stent trials a case for standardized definitions. Circulation, 2007, 115(17): 2344-2351 PMID: 17470709

[40] CampoG, ParrinelloG, FerraresiP, et al. . Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol, 2011, 57(25): 2474-2483 PMID: 21679849

[41] GiustiB, GoriAM, MarcucciR, et al. . Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol, 2009, 103(6): 806-811 PMID: 19268736

[42] MalekLA, PrzyluskiJ, SpiewakM, et al. . Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology, 2010, 117(2): 81-87 PMID: 20924183

[43] TirochKA, SibbingD, KochW, et al. . Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J, 2010, 160(3): 506-512 PMID: 20826260

[44] ShuldinerAR, O’ConnellJR, BlidenKP, et al. . Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 2009, 302(8): 849-857 PMCID: 3641569 PMID: 19706858

[45] BoumanHJ, SchömigE, van WerkumJW, et al. . Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med, 2010, 17(1): 110-116 PMID: 21170047

[46] ZouJJ, XieHG, ChenSL, et al. . Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. Eur J Clin Pharmacol, 2013, 69(4): 771-777 PMID: 23001453

[47] XieX, MaYT, YangYN, et al. . CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One, 2013, 8(3): e59344 PMCID: 3595238 PMID: 23555019

[48] JeongYH, TantryUS, KimIS, et al. . Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv, 2011, 4(6): 585-594 PMID: 22045970

[49] JohnsonJA, RodenDM, LeskoLJ, et al. . Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther, 2012, 91(5): 774-776 PMCID: 3382015 PMID: 22513313

[50] TierneyJF, StewartLA, GhersiD, et al. . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8(1): 16 PMCID: 1920534 PMID: 17555582

[51] AndersonJL, MowereCP, HomeBD, et al. . Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel. J Am Coll Cardiol, 2009, 53(10): A27-A28

[52] MegaJL, ThakuriaJV, CannonCP, et al. . Sequence variation in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insight from the CLARITY-TIMI 28 genomic study. J Am Coll Cardiol, 2008, 51(10): A206

[53] PengY, ChenM, LiuXJ, et al. . The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease. Atherosclerosis, 2013, 227(1): 106-111 PMID: 23337798